Status:
COMPLETED
Digital Health Intervention to Support Opioid Use Disorder Treatment
Lead Sponsor:
Rhode Island Hospital
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Opioid Use Disorder
Treatment Adherence
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In prior studies, the investigative team developed a combined computer- and text message-delivered personalized-feedback intervention (iENDURE) designed to enhance motivation and improve tolerance of ...
Detailed Description
Medication for Opioid Use Disorder (MOUD), which includes the use of Methadone, Buprenorphine, or long-acting Naltrexone, is an evidence-based approach to the treatment of Opioid Use Disorder. Bupreno...
Eligibility Criteria
Inclusion
- age 18+ years; current DSM-5 diagnosis of Opioid Use Disorder; current buprenorphine prescription; and access to cell phone with text message capability.
Exclusion
- active suicidality and/or psychosis; not fluent in English; not having a phone data plan.
Key Trial Info
Start Date :
October 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 15 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03842384
Start Date
October 1 2020
End Date
November 15 2023
Last Update
April 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rhode Island Hospital
Providence, Rhode Island, United States, 02903